Aurobindo Pharma Ltd logo

Aurobindo Pharma Ltd

AUROPHARMA NSE

Key Fundamentals

MidcapPharmaceuticalsHealthcare
Market Cap
₹94,529 Cr
Volatility
Moderate
P/E Ratio
25.74
EBITDA
₹7,338 Cr
Return on Equity
9.25%
Debt to Equity
0.21
Book Value
₹652.39
EPS
₹61.22
52W High
₹1,682.4
52W Low
₹1,016.1

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Aurobindo Pharma Ltd insights

57 extracted metrics + investor summaries across FY07–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Weaknesses

3
  • The company has delivered a poor sales growth of 6.32% over past five years.
  • Company has a low return on equity of 10.8% over last 3 years.
  • Company might be capitalizing the interest cost

Growth Rate

Revenue Growth
5.56% ↘
Net Income Growth
0.56% ↘
Cash Flow Change
40.81% ↗
ROE
-13.31% ↘
ROCE
-13.72% ↘
EBITDA Margin (Avg.)
-3.50% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 5d ago
AI opinion · based on fundamentals
Risk medium

Aurobindo Pharma trades at a market cap of ₹96,520 crore with a PE of 26.1x. The stock has delivered a strong 55% return over the past year, though underlying sales growth has been modest at 6% CAGR over five years. Return on equity remains subdued at around 10-11% over recent years.

Bull Case 7
  • Stock has delivered 55% returns over the past 1 year, significantly outperforming broader markets
  • Compounded profit growth of 23% over 3 years indicates meaningful earnings recovery
  • TTM profit growth at 11% shows continued earnings momentum on a higher base
  • 3-year stock CAGR of 24% reflects sustained re-rating by the market
  • 10-year compounded sales growth of 9% demonstrates consistent long-term revenue scaling
  • 10-year ROE average of 14% suggests the business has historically generated reasonable returns on capital
  • TTM sales growth of 9% is an improvement over the 5-year CAGR of 6%, indicating acceleration in revenue trajectory
Bear Case 8
  • 5-year compounded sales growth of just 6% reflects sluggish top-line expansion for a pharma company of this scale
  • 3-year ROE of only 11% and last year ROE of 10% are below cost of equity for most investors
  • Stock trades at 2.55x book value despite delivering sub-par return on equity of 10-11%
  • 5-year compounded profit growth of only 1% shows near-zero earnings expansion over a half-decade period
  • Dividend yield of just 0.24% provides negligible income return to shareholders
  • PE of 26.1x is elevated given the modest single-digit sales growth profile
  • Potential capitalization of interest costs may overstate reported profits and asset values
  • 10-year stock CAGR of only 8% suggests prolonged periods of underperformance despite recent rally

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 20h ago
Headwinds 1
  • Eugia gets US FDA warning letter Aug 14

    Eugia Pharma Specialities received a US FDA warning letter. Unit accounts for ~2% of Aurobindo's total revenue; current US supplies remain unaffected but regulatory overhang persists.

Positives 6
  • Q1FY27 profit surges 25% YoY Aug 5

    Aurobindo reported Q1FY27 net profit of ₹1,033 crore, up 25-32% YoY, driven by 16.3% revenue growth to ₹91,503.5 million and strong US performance.

  • HIV drug license with MSD Jul 24

    Aurobindo signed a royalty-free voluntary license with MSD to supply generic alimtravir to 129 low- and middle-income countries, a first in pre-phase 3 licensing for HIV prevention.

  • A1 Biochem 80% stake acquisition Jul 23

    Subsidiary Apitoria Pharma approved acquisition of 80% stake in A1 Biochem Group for USD 17 million to build a CRDMO platform.

  • Brazil ANVISA facility approval Jul 21

    CuraTeQ Biologics received ANVISA approval for its Hyderabad biosimilar manufacturing facility, opening access to Brazil and Latin America markets.

  • FY26 revenue up, Europe surges 23% Aug 3

    FY26 standalone revenue rose 2.2% to ₹111,717 crore with net profit up 0.5%. Europe revenue surged 23.4%, offsetting a 2.7% US decline; EBITDA margins held above 20%.

  • Eugia $500M FY27 revenue target Aug 6

    Management set a $500 million revenue target for Eugia by FY27, signalling confidence in the injectable business segment's growth trajectory.

Neutral 4
  • Auropharm Overseas subsidiary set up Aug 13

    Aurobindo incorporated wholly owned subsidiary Auropharm Overseas Limited in India for domestic and foreign manufacturing and marketing operations.

  • 39th AGM scheduled Aug 27 Jul 29

    Annual General Meeting set for August 27, 2026 via video conferencing. Share transfer books closed August 26-27.

  • Nuvama India Conference attendance Aug 6

    Aurobindo officials will participate in Nuvama India Conference 2026, August 11-13, with meetings in Singapore and Hong Kong.

  • FY26 BRSR report filed Aug 3

    Aurobindo submitted its Business Responsibility & Sustainability Report for FY26 detailing ESG metrics and renewable energy progress under SEBI regulations.

TL;DR: Aurobindo Pharma is delivering strong earnings growth with Q1FY27 profit up 25% YoY, supported by robust US performance and European expansion. Strategic moves into biosimilars (Brazil approval), CRDMO (A1 Biochem acquisition), and HIV generics (MSD deal) diversify its growth levers. The FDA warning letter on Eugia is a contained risk at ~2% of revenue but warrants monitoring. The trend is improving with earnings momentum, geographic diversification, and pipeline expansion outweighing the limited regulatory headwind.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
6,851
7,219
7,352
7,580
7,567
7,796
7,979
8,382
7,868
8,286
8,646
8,853
9,150
Expenses
5,702
5,846
5,753
5,920
5,949
6,230
6,401
6,622
6,265
6,608
6,873
7,103
7,271
Operating Profit
1,149
1,373
1,599
1,660
1,618
1,566
1,578
1,760
1,603
1,678
1,773
1,750
1,880
OPM %
17%
19%
22%
22%
21%
20%
20%
21%
20%
20%
21%
20%
21%
Other Income
47
188
163
14
221
136
159
135
107
122
123
117
224
Interest
57
68
76
89
111
113
118
115
98
95
93
98
102
Depreciation
327
418
423
354
404
382
419
444
406
429
465
479
487
PBT
812
1,076
1,262
1,230
1,324
1,207
1,200
1,335
1,207
1,276
1,339
1,291
1,515
Tax %
30%
30%
26%
26%
31%
32%
30%
32%
32%
34%
32%
29%
32%
Net Profit
570
752
940
907
918
817
846
903
824
848
910
921
1,032
EPS in Rs
9.74
12.92
15.98
15.51
15.69
14.07
14.56
15.56
14.2
14.61
15.67
15.86
17.78
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
12,103
13,772
14,910
16,463
19,564
23,099
24,775
23,455
24,855
29,002
31,724
33,653
34,935
Expenses
9,524
10,579
11,469
12,691
15,612
18,249
19,497
19,060
21,148
23,176
25,164
26,783
27,854
Operating Profit
2,579
3,193
3,441
3,772
3,952
4,849
5,278
4,396
3,707
5,826
6,560
6,870
7,081
OPM %
21%
23%
23%
23%
20%
21%
21%
19%
15%
20%
21%
20%
20%
Other Income
81
200
115
105
70
166
3,195
152
291
366
613
404
586
Interest
160
257
67
78
263
305
74
49
140
290
457
384
388
Depreciation
333
392
428
558
668
967
1,055
1,127
1,245
1,522
1,649
1,778
1,859
PBT
2,168
2,744
3,061
3,241
3,091
3,743
7,344
3,373
2,612
4,380
5,066
5,112
5,420
Tax %
28%
26%
25%
25%
24%
24%
27%
22%
26%
28%
31%
31%
—
Net Profit
1,571
2,024
2,301
2,423
2,364
2,844
5,334
2,647
1,928
3,169
3,484
3,503
3,711
EPS in Rs
26.98
34.61
39.29
41.36
40.36
48.56
91.05
45.2
32.9
54.15
60.02
60.34
63.92
Div. Payout %
8%
7%
6%
6%
6%
6%
4%
20%
23%
8%
0%
7%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
29
59
59
59
59
59
59
59
59
59
58
58
Reserves
5,127
7,229
9,313
11,622
13,832
16,766
21,871
24,517
26,781
29,784
32,595
37,833
Borrowings
4,451
5,041
3,364
4,770
6,967
5,826
5,339
2,851
5,286
6,648
8,263
8,073
Other Liabilities
3,303
3,568
3,464
4,492
5,414
6,113
6,147
6,211
7,379
8,227
8,566
12,232
Total Liabilities
12,910
15,896
16,200
20,942
26,271
28,765
33,416
33,638
39,505
44,717
49,482
58,196
Fixed Assets
3,706
4,180
4,834
6,521
8,475
9,396
9,374
10,532
11,024
14,493
14,794
17,407
CWIP
420
848
1,458
1,583
1,668
1,986
3,062
3,747
5,390
3,869
4,900
5,214
Investments
20
123
246
312
360
555
591
997
543
372
252
1,051
Other Assets
8,765
10,745
9,662
12,527
15,768
16,827
20,390
18,362
22,549
25,983
29,536
34,525
Total Assets
12,910
15,896
16,200
20,942
26,271
28,765
33,416
33,638
39,505
44,717
49,482
58,196
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
1,237
1,420
3,279
1,955
1,651
4,381
3,329
5,016
2,387
2,435
3,925
5,526
Investing
-1,017
-1,446
-1,787
-1,927
-2,904
-1,563
597
-3,211
-3,971
-4,242
-1,866
-2,630
Financing
93
365
-1,915
864
1,919
-1,947
-1,365
-2,969
1,814
800
120
-1,269
Net Cash Flow
313
340
-424
892
666
871
2,561
-1,164
230
-1,007
2,178
1,628
Free Cash Flow
491
-146
1,594
714
114
2,969
1,503
2,693
-323
-1,067
1,408
2,468
CFO/OP
67
67
118
70
61
106
87
143
84
72
86
107
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
107
122
68
68
64
68
52
62
66
61
66
77
Inventory Days
239
240
246
317
304
289
333
272
275
284
295
326
Days Payable
136
146
122
128
107
97
103
97
125
129
117
151
Cash Conversion Cycle
210
217
191
257
260
260
282
237
216
216
244
252
Working Capital Days
50
44
51
50
25
35
52
84
55
66
49
44
ROCE %
27%
27%
25%
23%
18%
19%
18%
13%
9%
14%
14%
13%

Shareholding Pattern

As of Jun 2026
Promoters 51.88%
DIIs 25.10%
FIIs 16.38%
Public 5.36%
Others 1.28%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
51.94%
51.83%
51.83%
51.83%
51.83%
51.83%
51.83%
51.83%
51.83%
51.83%
51.83%
51.83%
51.83%
51.80%
51.82%
51.82%
51.82%
51.82%
51.82%
51.82%
51.82%
51.88%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.01%
0.00%
0.00%
0.00%
0.00%
18.02%
16.73%
16.59%
16.29%
15.33%
14.37%
14.21%
13.94%
15.24%
16.38%
DIIs
10.99%
12.72%
13.82%
15.11%
15.83%
15.58%
16.23%
14.89%
15.08%
15.73%
17.94%
20.23%
23.28%
24.77%
25.13%
25.20%
26.23%
26.93%
27.60%
27.68%
25.87%
25.10%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
8.71%
8.54%
9.60%
8.99%
8.37%
8.80%
8.65%
9.42%
8.54%
7.01%
6.15%
5.64%
5.52%
5.47%
5.33%
5.52%
5.47%
5.67%
5.25%
5.36%
5.74%
5.36%
Others
28.36%
26.91%
24.74%
24.07%
23.97%
23.79%
23.29%
23.85%
24.54%
25.42%
24.07%
22.29%
1.36%
1.23%
1.13%
1.17%
1.15%
1.20%
1.13%
1.19%
1.34%
1.28%
No. of Shareholders
2,32,634
2,43,315
3,29,940
3,41,568
3,38,639
3,59,684
3,58,459
3,69,828
3,43,617
2,93,214
2,59,638
2,41,944
2,44,575
2,38,622
2,48,488
2,57,962
2,69,323
2,72,208
2,47,662
2,36,859
2,41,298
2,39,073

Documents

1
Concall - May 2017 May 2017
2
Concall - Jun 2017 Jun 2017
3
Concall - Jun 2017 Jun 2017
4
Concall - Jun 2017 Jun 2017
5
Concall - Aug 2017 Aug 2017

Frequently Asked Questions about Aurobindo Pharma Ltd

What does Aurobindo Pharma Ltd do?
Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)
Where is Aurobindo Pharma Ltd (AUROPHARMA) listed?
Aurobindo Pharma Ltd is listed on the Indian stock exchanges. It is listed on NSE: AUROPHARMA and BSE: 524804. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Aurobindo Pharma Ltd belong to?
Aurobindo Pharma Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Aurobindo Pharma Ltd?
Aurobindo Pharma Ltd has a market capitalisation of approximately ₹94528.83 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Aurobindo Pharma Ltd?
The Price-to-Earnings (PE) ratio of Aurobindo Pharma Ltd is 25.74. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Aurobindo Pharma Ltd?
Over the past 52 weeks, Aurobindo Pharma Ltd has traded between a low of ₹1,016.1 and a high of ₹1,682.4. This range helps investors understand the stock's price volatility and recent trading levels.
Does Aurobindo Pharma Ltd pay dividends?
Yes, Aurobindo Pharma Ltd has a dividend yield of 0.25%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Aurobindo Pharma Ltd?
Aurobindo Pharma Ltd has a Return on Equity (ROE) of 9.25%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Aurobindo Pharma Ltd on Tapetide?
On Tapetide, you can view Aurobindo Pharma Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)

Website aurobindo.com
CEO Mr. Kambam Nithyananda Reddy
Employees 27,707
Listed 1995-04-06
Face Value ₹ 1
Issued Size 58,08,01,623

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List